Generate Biomedicines Raises $400 Million in Nasdaq IPO
SOMERVILLE, Mass., February 27, 2026 — Generate Biomedicines Inc. announced the completion of its initial public offering, raising $400 million through the sale of 25 million shares priced at $16 each on Nasdaq under the ticker GENB. The Flagship Pioneering-backed artificial intelligence biotech company will deploy proceeds to fund Phase 3 clinical trials for its lead asthma treatment and expand its generative biology platform.
Deal Structure
Generate priced shares at the midpoint of its $15-$17 range, generating $400 million in gross proceeds before underwriting discounts. Goldman Sachs and Morgan Stanley served as lead bookrunners, with Piper Sandler, Guggenheim Securities, and Cantor as co-managers. Trading commenced February 27, 2026, with the offering scheduled to close March 2. Underwriters received a 30-day option to purchase an additional 3.75 million shares.
The Somerville, Massachusetts-based company utilizes generative AI to design protein therapeutics. Its lead candidate, GB-0895, an anti-TSLP antibody for severe asthma, is entering Phase 3 trials through the SOLAIRIA program with global enrollment underway. Additional pipeline assets include GB-4362 in Phase 1 oncology studies and GB-5267, a CAR-T therapy targeting ovarian cancer. Generate previously secured $273 million in Series C funding in 2023 and generated $110 million through collaborations with Amgen and Novartis. The company reported a net loss of $223 million in 2025.
Industry Context
Generate’s IPO marks the fifth biotech public offering in February 2026, with the sector raising nearly $1.4 billion during the month compared to $915 million in the prior-year period. Newly listed biotech companies gained an average of 41% following their debuts, signaling robust investor appetite for Phase 2/3 clinical assets and AI-driven drug discovery platforms. The oversubscribed offering reflects market confidence in generative biology despite operating losses, mirroring technology-driven disruption patterns observed in financial services.
While primarily U.S.-focused, Generate’s global clinical trial network and manufacturing partnerships with organizations including Lonza and WuXi demonstrate biotech’s internationally integrated supply chains.
Conclusion
Proceeds will advance GB-0895 Phase 3 enrollment with topline data expected in H1 2028, support Phase 1 data generation for GB-4362 and GB-5267, and fund preclinical programs as Generate positions itself as a pioneer in generative biology drug development.
Sources: Bloomberg, Yahoo Finance, Generate Biomedicines, BioPharma Dive, SEC
